MétaCan
Menu
← Back to cohort

RECOGNISE: Rasagiline Effects on Cognition in Parkinson’s Patients with Mild Cognitive Impairment (P2.343)

2016· article· en· W2534311425 on OpenAlexaboutno aff
R. J. Mills, Ishita Gambhir, Jill Farmer, Fernando Pagán

Bibliographic record

VenueNeurology · 2016
Typearticle
Languageen
FieldMedicine
TopicAttention Deficit Hyperactivity Disorder
Canadian institutionsnot available
Fundersnot available
KeywordsRasagilineCognitionCognitive impairmentMedicineParkinson's diseasePsychiatryInternal medicineDisease

Abstract

fetched live from OpenAlex

Objective Randomized, double-blinded, placebo- controlled trial evaluating effects of Rasagiline 1mg/day on cognitive function in patients with Idiopathic Parkinson’s Disease (PD) and Mild Cognitive Impairment(MCI) as assessed by the Montreal Cognitive Assessment (MOCA), Frontal Assessment Battery test (FAB), and Scales for Outcomes in Parkinson’s Disease-Cognition-test (SCOPA-COG). Background Rasagiline is an irreversible monoamine oxidase inhibitor that blocks monoamine oxidase type B and enhances central dopaminergic transmission. The enhancement of dopaminergic function has been associated with improvements in executive abilities. Mild cognitive deficits in PD are associated with functional impairment, poorer quality of life and caregiver burden. Given MCI in PD invariably precedes Parkinson’s disease dementia (PDD), a treatment that could improve cognition and/or delay conversion from MCI in PD to PDD would have a significant impact. Method Patients meeting the inclusion and exclusion criteria were randomly assigned a treatment drug, either placebo or Rasagiline. Patients underwent motor and cognitive testing at baseline and at 14 weeks. Secondary endpoints include assessment of changes in UPDRS, depression, and balance. Results 34 subjects completed the study out of 40 enrolled (65.2[percnt] male, mean age 68.1 years, diagnosed with PD mean 6.0 years, mean years of education 16.8). There appeared to be a trend in improvement in total MOCA final score from baseline in the Rasagaline group (p=0.001) compared to placebo(p=0.067). There were no significant improvements in FAB, SCOPA-COG or secondary endpoints in the Rasagaline group compared to placebo. SCOPA-COG was not an effective measure of cognition due to its long duration and frequent “wearing off” of subjects during test administration. Conclusion Thus far, no standard-of-care medications for Idiopathic Parkinson’s Disease have been shown to significantly enhance cognition. We conclude that Rasagaline may have mild cognitive enhancing properties, however further larger studies are needed to validate the positive trend shown in our study.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.008
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.273
Teacher spread0.257 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueNeurology→Same topicAttention Deficit Hyperactivity Disorder→French-language works237,207→